Last reviewed · How we verify
relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation
Approved treatments
- Ojemda · Day One Biopharms
Ojemda works by blocking the BRAF protein, which is a key driver of cancer cell growth and survival.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation patent landscape — cliff calendar, originator estates, attackable patents
- relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation treatment landscape brief
- relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation treatment updates RSS
Frequently asked questions about relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation
What drugs treat relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation?
Tracked treatments include Ojemda.
What is the treatment for relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation?
Standard treatment for relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation includes Ojemda. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation patent cliff · relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF V600 mutation CI report
- Treatment: Ojemda · Day One Biopharms
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing